Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CA7 | P43166 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.58 |
| ▸ | ESR1 | P03372 | 1/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.53 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 5/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL245250 | 0.95 | CA1 (0.63) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8373733 | 0.88 | SMN1; SMN2 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL15672816 | 0.87 | CA1 (0.63) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1965326 | 0.87 | CA1 (0.73) | CA12CA1CA2CA7CA9 | |
| SCHEMBL16351874 | 0.87 | CA1 (0.73) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9468569 | 0.87 | CA12 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8026628 | 0.87 | CA12 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5863216 | 0.85 | NPC1 (0.51) | SMN1; SMN2CYP4F2CYP4A11HPGDNPC1 | |
| SCHEMBL4726691 | 0.85 | BCL2 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8026489 | 0.84 | CA12 (0.59) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220363709-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2022-11-17 | — | — | US | disclosed |
| EP-3986894-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | Calithera Biosciences, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-114008048-A | Exonucleotidase inhibitors and methods of use thereof | 卡利泰拉生物科技公司 | 2022-02-01 | — | — | CN | disclosed |
| WO-2020257429-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | CALITHERA BIOSCIENCES, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2009071504-A1 | 2,6-DISUBSTITUTED PYRIDINES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |
| US-7132456-B2 | MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2006-11-07 | — | — | US | disclosed |
| US-20060052449-A1 | Novel mch receptor antagonists | ELI LILLY AND COMPANY | 2006-03-09 | — | — | US | disclosed |
| EP-1572637-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004052848-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
| US-5700938-A | Intermediates for imidazopyridine derivatives | EISAI CO., LTD. (JP) | 1997-12-23 | — | — | US | disclosed |
| US-5618969-A | Intermediates for imidazopyridines | EISAI CO., LTD. (JP) | 1997-04-08 | — | — | US | disclosed |
| US-5608068-A | Process for the preparation of imidazopyridine derivatives and intermediates | EISAI CO., LTD. (JP) | 1997-03-04 | — | — | US | disclosed |
| US-5587504-A | Sulfonyloxy-biphenylcarboxylic ester derivatives which are intermediates | EISAI CO., LTD. (JP) | 1996-12-24 | — | — | US | disclosed |
| US-5583229-A | Process for the preparation of imidazopyridine derivatives | EISAI CO., LTD. (JP) | 1996-12-10 | — | — | US | disclosed |
| US-5559236-A | Intermediates for substituted biphenylmethylmidazopyridine angiotensin II antagonists | EISAI CO., LTD. (JP) | 1996-09-24 | — | — | US | disclosed |
| US-5557002-A | Process for the preparation of biphenyl containing intermediates useful in making angiotensin II receptor antagonists | EISAI CO., LTD. (JP) | 1996-09-17 | — | — | US | disclosed |
| US-5554757-A | Process for the preparation of imidazopyridine derivatives, and intermediates therefore | EISAI CO., LTD. (JP) | 1996-09-10 | — | — | US | disclosed |
| EP-0627433-A1 | PROCESS FOR PRODUCING IMIDAZOPYRIDINE DERIVATIVE AND INTERMEDIATE | Eisai Co., Ltd. (JP) | 1994-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363709-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | CA12 1613/4885CA1 1237/4885CA2 356/4885 |
| US-20060052449-A1 | Novel mch receptor antagonists | MCHR1, MCHR2, MC1R | CA12 4483/4885CA1 4641/4885CA2 2525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.